tbuckley/cabot-search huggingface dataset:
Effect of Sex and Sporting Discipline on LV Adaptation to Exercise
Authors: Gherardo Finocchiaro, Harshil Dhutia, Andrew D’Silva, Aneil Malhotra, Alexandros Steriotis, Lynne Millar, Keerthi Prakash, Rajay Narain, Michael Papadakis, Rajan Sharma, Sanjay Sharma
Journal: JACC. Cardiovascular imaging (2016)
Caspofungin Primary Antifungal Prophylaxis in Acute Leukemia Patients During Induction Therapy: Results of a Prospective Phase II Multicentric Study (ProfilC Study).
Authors: Chiara Cattaneo, Simona Monte, Alessandra Algarotti, Ernesta Audisio, Erika Borlenghi, Barbara Bottazzi, Leonardo Campiotti, Elisa Cerqui, Caterina Micò, Marilena Romero, Flavia Salvi, Anna Salvi, Gianni Tognoni, Alberto Mantovani, Teodoro Chisesi, Alessandro Levis, Giorgio Lambertenghi Deliliers, Enrico Pogliani, Alessandro Rambaldi, Giuseppe Rossi
Journal: Blood (2009)
Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.
Authors: Hiroto Inaba, Jeffrey E Rubnitz, Elaine Coustan-Smith, Lie Li, Brian D Furmanski, Gerard P Mascara, Sheila A Shurtleff, Stanley B Pounds, Ching-Hon Pui, Raul C Ribeiro, Dario Campana, Sharyn D Baker
Journal: Blood (2010)
Soft-Tissue Sarcomas in Adults
Authors: Matthew A. Clark, Cyril Fisher, Ian Judson, J. Meirion Thomas
Journal: New England Journal of Medicine (2005)

Soft-tissue sarcomas have traditionally been managed by wide excisional surgery and radiotherapy, with chemotherapy reserved for advanced disease. However, advances in multidisciplinary care have improved the evaluation and treatment of patients with this uncommon tumor. Limb-conserving surgery, superior radiotherapy delivery, and novel adjuvant agents for specific tumors are now available. This article reviews the current understanding and treatment of soft-tissue sarcoma, with an emphasis on recent advances.
Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation
Authors: Don Benson, Leslie Andritsos, Mehdi Hamadani, Thomas Lin, Joseph Flynn, Jeffrey Jones, William Blum, Patrick Elder, Gerard Lozanski, John Byrd, Steven Devine
Journal: Blood (2008)
A Multicentre Retrospective UK Study Detailing Onset Of Graft Verus Host Disease, Responses To Treatment and Outcome After Donor Lymphocyte Infusion Following Haemopoietic Stem Cell Transpantation: Rates Of GVHD Are High But Death From GVHD Infrequent
Authors: Julia J Scarisbrick, Fiona L Dignan, Sameer Tulpule, Emma Das gupta, Gulnaz Shah, Antonio Pagliuca, Ram Malladi, Kavita Raj
Journal: Blood (2013)
SAT0599 Autoimmnune Disease in Acute Coronary Syndromes. Clinical Implications
Authors: N. Lozano-Rivas, C. Marras-Fernández Cid, P. Flores-Blanco, F.J. Pastor-Perez, L.F. Linares, F.A. Martinez-Angosto, J. Martínez-Ferrin, S. Manzano-Fernández
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with autoimmune diseases (AID) have a high burden of cardiovascular disease leading to premature morbidity and mortality<sup>1</sup>. But it is unclear if it is due to a higher prevalence of cardiovascular disease, to a worse case fatality or to a different management after an index event. <h3>Objectives</h3> The aim of the study is to assess the prevalence of AID in patients with acute coronary syndrome (ACS), the management and prognostic implications. <h3>Methods</h3> The study included consecutive patients admitted after ACS from January 2011 to May 2014. For AID patients, in-hospital management and ACS presentation was compared to non-AID patients. We also compared in-hospital and 1-year major adverse events (MACE): death, recurrent myocardial infarction, stroke and major bleeding, between groups. The percentage lost to follow-up was &lt;1%. <h3>Results</h3> Of 964 patients, 53 had AID (5.5%): 11 rheumatoid arthritis, 9 inflammatory bowel disease, 7 ankylosing spondylitis, 7 psoriatic arthritis, 5 polymyalgia rheumatica, 4 systemic lupuserythematosus and 10 miscellanea. Mean evolution of the disease was 14±3 years. No significant differences were found in clinical and demographics characteristics between groups except for a higher percentage of previous stable coronary heart disease in non-AID patients. Compared to non-AID patients, AID patients had similar clinical ACS presentation and no differences were found with respect to revascularization strategies or medical treatment at discharge. Overall there were 207 MACE (69% during hospitalization): 108 deaths, 52 recurrent myocardial infarctions, 19 ischemic strokes and 28 major bleedings. The two groups had comparable rates of MACE both during hospitalization (9.6% vs 12.2%, p=0.58) and at 1 year (26.4% vs 19.1%, p=0.19), AID vs non-AID respectively. The presence of AID was not associated with increased in-hospital mortality (OR 1.1, 95% CI 0.4 to 3.3) but it was a risk factor for higher 1-year crude mortality (OR 2.2, 95% CI 1.1 to 4.4), with a trend to higher 1-year mortality after multivariable adjusting (OR 1.7, 95%CI 0.8 to 3.9). <h3>Conclusions</h3> The presence of AID did not change ACS presentation and clinical management. Moreover it is not independently associated with worse outcomes during hospitalization although there is a trend to higher 1-year mortality. <h3>References</h3> Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol. 2011 May 31;7(7):399–408 <h3>Disclosure of Interest</h3> None declared
FRI0180 No Prediction of Relapse by TNF Blocker Concentrations or Detection of Antibodies against anti-TNF: Data from Strass Study
Authors: H. Marotte, M. Rinaudo, S. Paul, B. Fautrel
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The goal of rheumatoid arthritis (RA) strategy is to reach remission or at least a low disease activity. When this gaol is reached, no clear guideline exist to manage therapy. Recently, STRASS (<i>Spacing TNF-blocker injections in RA Study</i>) provided evidence of step-down therapeutic strategy with adalimumab or etanercept (1). <h3>Objectives</h3> We investigated if drug dosages and their antidrug antibodies (ADAb) could predict relapse during the 18 months of STRASS study. <h3>Methods</h3> We assessed 131 serum among the 137 included in STRASS study (60 and 71 for adalimumab and etanercept, respectively). Serum were collected at the time of randomisation. Adalimumab and etanercept blood concentrations and theirs ADAb were assessed by ELISA (Theradiag, Marne-La-Vallee, France). For this study, relapse was defined as DAS28&gt;2.6 with DAS28 increase &gt;0.6 since the previous study visit. <h3>Results</h3> Characteristics of the 131 patients similar to 137 from the initial STRASS study (data not shown). The median age was 54.5 [48.3–61.8] years. One hundred and two (77%) were female. The median disease duration was 6.5 [4.5–12.4] years. The median DAS28, ESR, and CRP were 2.0 [1.5–2.3], 10 [6–17], and 3 [2–4]mg/mL, respectively. Methotrexate was the main DMARDs used (n=91; 70%). No baseline characteristics were associated with relapse during tapering or not. In patients treated with etanercept, etanercept level was similar in case of relapse or not. Similarly, adalimumab level was comparable in case of relapse or not. However, in patients treated with adalimumab, ADABs was significantly higher in case of relapse compared to no relapse (0.94±0.27 ng/ml <i>vs.</i> 0.27±0.76 ng/ml; P=0.03, respectively). However, this difference was not clinically pertinent. <h3>Conclusions</h3> No difference was observed in adalimumab or etanercept blood level to predict relapse in RA patients with low disease activity. However, a slight increased of ADAb for adalimumab was observed. Its signification needs further investigation. <h3>References</h3> Fautrel B, Pham T, Alfaiate T, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases 2016; 75: 59–67. <h3>Acknowledgement</h3> AbbVie provided funding for this study. Analysis was performed independently to AbbVie. <h3>Disclosure of Interest</h3> None declared
Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation
Authors: Christophe Willekens, Angelo Paci, Serge Koscielny, Alice Marceau, Jean-Baptiste Micol, Sophie Broutin, Cyril Quivoron, Véronique Saada, Vianney Poinsignon, Franck Griscelli, Vincent Ribrag, Cristina Castilla-Llorente, Claude Preudhomme, Virginie Lacronique-Penard, Stéphane De Botton
Journal: Blood (2015)
A New Cell-Cycle Target in Cancer — Inhibiting Cyclin D–Dependent Kinases 4 and 6
Authors: Charles J. Sherr
Journal: New England Journal of Medicine (2016)

Unlike traditional cytotoxic drugs, CDK4–CDK6 inhibitors arrest progression through the G1 phase, promoting transient cell-cycle withdrawal into a quiescent state or, possibly, permanent proliferative arrest (senescence), either of which could avert tumor progression.
Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia
Authors: Annie Im, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Seah H. Lim, Robert Redner, Alison R. Sehgal, Kathleen A. Dorritie, Ann Welsh, Linda Fukas, Christine Tripoli, Daniel Normolle, Daniel E Johnson, Michael Boyiadzis
Journal: Blood (2015)
Metabolic Targeted Therapy for Aggressive B-Cell Lymphomas: Evaluating Glucose Metabolism and the Potential of 187rhenium- Ethylenedicysteine –N-AcetylGlucosamine (187Re-ECG) for Therapy
Authors: Lan V Pham, Jerry Bryant, Archito Tamayo, Richard Mendez, Edna Chum, David Yang, David Rollo, Richard J. Ford
Journal: Blood (2010)
Late Cardiotoxicity of Intensive Modified Program NHL-BFM-90 in Adult Poor Prognosis Patients with Diffuse Large B-Cell Lymphoma
Authors: Elena Dorokhina, Aminat Umaraskhabovna Magomedova, Alexander Shevelev, Sergei M Kulikov, Michael Gitis, Alexey Vedernikov, Alexey Vedernikov, Andrey Vorobiev, Sergey Kravchenko, Valeri G Savchenko
Journal: Blood (2015)
PO02CHARACTERISATION OF GLIOBLASTOMA METABOLISM IN-VITRO: A COMPARISON BETWEEN A CELL LINE AND PRIMARY CULTURES
Authors: M. Waqar, R. Richards, V. See
Journal: Neuro-Oncology (2015)

INTRODUCTION: Characterisation of glioblastoma (GBM) metabolism is important clinically. The extent to which well-characterised cell lines represent tumour metabolism is poorly described. This study aimed to compare metabolic biomarker expression patterns between a commonly used cell line (U87-MG) and primary GBM cells, in two and three dimensional culture systems. METHOD: U87-MG and primary GBM cells were cultured in serum containing media. Multicellular tumour spheroids were produced by culturing cells in hanging droplet media. Immunofluorescence and fluorescence intensity quantification were used to assess the expression patterns of the following biomarkers: carbonic anhydrase 9 (CA9), glucose transporter 1 (GLUT1), monocarboxylate transporter 4 (MCT4) and glial fibrillary acidic protein (GFAP, control). Independent t-tests (t-t) were used to compare groups. RESULTS: In monolayer culture, CA9 expression was significantly greater in the U87-MG cell line (t-t, t = 3.417, p = 0.012), though GLUT1 (t-t, t = 1.046, p = 0.354) and MCT4 (t-t, t = 0.956, p = 0.393) were similarly expressed. The cell line was also found to be GFAP negative in contrast to primary cultures (t-t, t = 4.323, p = 0.012). In U87-MG spheroids, MCT4 expression was relatively greater in the outermost regions (t-t, t = 2.830, p = 0.047), though CA9 and GLUT1 expression was largely homogeneous. In contrast, primary GBM spheroids displayed gradients of increasing expression towards the outer regions, for all metabolic biomarkers. CONCLUSION: There were differences in metabolic biomarker expression between the cell line and primary GBM cells, in both culture systems. Cell lines should be used with caution to model GBM metabolism.
Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort
Authors: Camille Roubille, Nathalie Rincheval, Maxime Dougados, René-Marc Flipo, Jean-Pierre Daurès, Bernard Combe
Journal: Annals of the Rheumatic Diseases (2017)

Objective To explore the 7-year tolerability profile of glucocorticoids (GC) for early rheumatoid arthritis (RA). Methods We examined data for 602 patients with RA from the early arthritis Etude et Suivi des POlyarthrites Indifférenciées Récentes (ESPOIR) cohort (&lt;6 months disease duration) stratified into two groups: with or without GC treatment at least once during follow-up (median 7 years (IQR 0.038–7.65)). The main outcome was a composite of death, cardiovascular disease (including myocardial ischaemia, cerebrovascular accident and heart failure), severe infection and fracture. Results Among the 602 patients with RA (476 women (79%), mean age 48±12 years), 386 with GC (64.1%) received low-dose prednisone (mean 3.1±2.9 mg/day for the entire follow-up): 263 started GC during the first 6 months (68%), and the mean duration of total GC treatment was 1057±876 days. As compared with patients without GC (216 (35.9%)), those with GC showed greater use of non-steroidal anti-inflammatory drugs, synthetic and biological disease-modifying antirheumatic drugs and had more active disease disability, higher C reactive protein and anticitrullinated protein antibody levels. Among 65 events (7 deaths, 14 cardiovascular diseases, 19 severe infections and 25 fractures), 44 and 21 occurred in patients with and without GC (p=0.520). Infections were more frequent, although not significantly, in patients with than without GC (p=0.09). On weighted Cox proportional-hazards analysis, with use of propensity score and inverse-probability-of-treatment weighting, and including age, gender, history of hypertension and GC treatment, outcomes did not differ with and without GC (p=0.520; HR=0.889; 95% CI 0.620 to 1.273). Conclusions This 7-year analysis of the ESPOIR cohort supports the good safety profile of very low-dose GC for early active RA.
Antibodies Directed Against the Domain 1 of Beta2-Glicoprotein 1 May be Associated with Secondary Antiphospholipid Syndrome
Authors: Silmara Aparecida De Lima Montalvao, Priscila Elidio Soares, Sabrina Saraiva, Bruna Moraes Mazetto, Marina Pereira Colella, Erich Vinicius De Paula, Simone Appenzeller, Joyce Maria Annichino-Bizzacchi, Fernanda Andrade Orsi
Journal: Blood (2015)
MLN4924, a Potent and Novel Small Molecule Inhibitor of Nedd8 Activating Enzyme, Induces DNA Re-Replication and Apoptosis in Cultured Human Tumor Cells
Authors: Michael Milhollen, Usha Narayanan, Jennifer Duffy, Ben Amidon, Teresa A Soucy, Allison J Berger, Steven P. Langston, Todd Sells, Peter G Smith
Journal: Blood (2008)
Stem Cell Transplantation (HSCT) in Patients with Autoimmune Disease (ADs). Results of a Single Center in Brazil.
Authors: Morgani Rodrigues, Andreza Alice Feitosa Ribeiro, Jose Mauro Kutner, Reijane Alves de Assis, Claudia Mac Donald Bley Nascimento, Morton Aaron Scheimberg, Roberto Carneiro, Charles Peter Tilbery, Pedro Paulo Porto Junior, Nelson Hamerschlak
Journal: Blood (2009)
OC-066 A National Survey of the Practice and Attitudes Towards Investigations and Biofeedback Therapy for Anorectal Disorders
Authors: DH Vasant, S Hamdy, K Solanki, S Senapati, L Smith, J Barlow, NV Radhakrishnan
Journal: Gut (2016)

<h3>Introduction</h3> Recent international consensus guidelines on anorectal disorders from the Neurogastroenterology and Motility societies (ANMS-ESNM) recommend biofeedback therapy (BFT) for constipation with dyssynergic defecation (DD) and for faecal incontinence (FI).<sup>1</sup> We conducted a national survey to understand the current practice and opinions on anorectal function tests and BFT in the UK &amp; Ireland. <h3>Methods</h3> An online survey was developed by a multi-disciplinary panel with medical, surgical and GI physiology representation. All GI clinicians and physiologists/scientists in the UK &amp; Ireland were invited to take the survey through their national societies BSG, AGIP, AUGIS and ACPGBI. All respondents were asked about their views on anorectal function tests and BFT, whilst GI physiologists and lead clinicians regularly involved in these studies were asked specific questions relating to their clinical practice. <h3>Results</h3> 313 responses (59% Gastroenterologists) included representatives from 98 GI physiology units. Of the units surveyed, 74% have anorectal manometry (ARM) (High Resolution 35%), 59% offer BFT and most have access to other imaging modalities (endoanal ultrasound 64%, colonic transit studies 86% and defecating proctography 67%). Overall, the majority agreed that anorectal function tests are useful in managing chronic functional constipation (FC) (69%) and FI (76%). In FI, 61% found BFT helpful, whereas opinions were divided in constipation with 52% finding BFT helpful for all forms of FC and 47% indicating BFT is only helpful in the DD sub-group. Surprisingly, a high proportion of respondents ‘did not know’ how useful anorectal function tests (FC 22% and FI 21%) and BFT (FC 26%, DD 33%, FI 31%) were. Responses from GI physiologists/lead clinicians (n = 95) indicated that; 58% have separate rooms for lower GI studies and the numbers of ARMs performed/month in their units (where known) were; none in 20%, 1–20 cases in 37% and &gt;20/month in 28% and similarly numbers of BFTs/month for DD, FC or FI were; none in 37%, 1–20 cases in 21%, &gt;20 in 18%. Only half the GI physiologists/lead clinicians surveyed offer BFT (FI 52%, DD 53% and FC 47%). <h3>Conclusion</h3> Whilst anorectal function tests are available in most units, BFT appears to be limited to specialist centres, with the majority agreeing that these interventions are useful in managing FC, DD and in particular FI. Up to a third were unsure about the utility of tests and BFT suggesting a worrying lack of knowledge and exposure amongst non-specialists which could affect the management of patients with these common anorectal disorders. <h3>Reference</h3> 1 Rao S, <i>et al</i>. <i>NMO</i> 2015;<b>27</b>(5):594–609. <h3>Disclosure of Interest</h3> None Declared
SP0111 Sonographic-Guided Joint and Periarticular Aspirations and Injections
Authors: N.S. Damjanov
Journal: Annals of the Rheumatic Diseases (2016)

For more than 60 years intra-articular an peri-articular injection are part of the standard treatment of arthritis. In vast majority of interventions needles used to be guided by anatomical landmarks as orientation ("blind" join injection). However, studies of the accuracy of "blind" injections into various joints showed that about two thirds of knee and ankle injections and only half of the wrist injections were intra-articular. The accuracy of blind corticosteroid injections into the glenohumeral joint is also questionable. Tobola et al. found the accuracy of an anterior approach glenohumeral injection was 64.7%, regardless of clinician experience. Utilizing the additional measure of ultrasound or another image modality to guide injections improves accuracy. In comparison to a blind posterior injection technique, ultrasound guided injections had a greater success rate of reaching of the glenohumeral joint (72.5% vs. 92.5%. Musculoskeletal ultrasound (MSUS) allows the possibility of reliable guidance of needle during diagnostic (e.g. needle aspiration of synovial liquid for analysis) and treatment interventions (e.g., intra-articular injections of drugs). Ultrasound guidance enables the exact placement of the needle into the structure of interest and accurate injection of medication. Moreover, it helps in establishing more precise diagnosis and in confirmation of the indication for injection. Ability of ultrasound guided injections to improve clinical outcomes compared to that of palpation guided injections however remains unclear. Lee et al. compared ultrasound-guided injections of triamcinolone with blind injections. At 6 weeks, the ultrasound guided injection group did not have statistically superior improvements than blind injections in flexion, abduction, external rotation or internal rotation, although improvements from baseline were significant within both groups (p&lt;0.001). The ultrasound guided injection group also did not have significantly better VAS score improvements after 3 weeks. On the contrary, one study showed that US guidance significantly improved the outcome of intra-articular steroid injections compared with anatomical palpation guidance. For successful implementation of ultrasound-guided injection technique appropriate training is required. After successful training, guidance of needle allows precise and successful diagnostic and/or treatment intervention. Moreover, ultrasound examination can visualize different tissues which could be damaged by the needle during the "blind" injection. Ultrasound visualization allows examiner to minimize possible damage of blood vessels, nerves, tendons, ligaments, cartilage and other tissues by the needle. Two main advantages of ultrasound-guided injections are increased accuracy and minimal risk of adverse events during and after the intervention. <h3>Disclosure of Interest</h3> None declared
Targeting Dysfunctional Myeloid Cells Delays Disease Development and Improves Immune Function in a CLL Mouse Model
Authors: Bola Hanna, Fabienne McClanahan, Nadja Zaborsky, Claudia Dürr, Verena Kalter, Alexander Egle, John G. Gribben, Peter Lichter, Martina Seiffert
Journal: Blood (2014)
Successful Pregnancy Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Long-Term Eculizumab Treatment
Authors: Richard Kelly, Louise Arnold, Stephen J. Richards, Anita Hill, Charlotte Bomken, John Hanley, Andrew Loughney, Gus Khursigara, Russell P. Rother, Elizabeth Chalmers, Edward Fitzsimons, Ryotaro Nakamura, Anna Gaya, Bruno Rotoli, Antonio M. Risitano, Joerg Schubert, Peter Hillmen
Journal: Blood (2008)
Multiple Myeloma, Detection of Four Unfavorable Genetic Pronostic Factor by Interphase Two-Color Fluorescence in Situ Hybridization Analyses: A Study of 33 Patients At Diagnosis or Relapse
Authors: Carlo Sergio Barragan, Silvia B. Hansson, Silvina A Cicchini, Federico J Hidalgo, Claudia E Ochoa, Gabriela Nunez, María Gabriela Flores, Teresa Salvador, Silvia Saba
Journal: Blood (2012)